NDUFAB1 and hepatocellular carcinoma: Patients with advanced HCC and well‐preserved liver function (CP A) have seen considerable improvement in treatment options since 2018, following completion of several Phase 3 studies in this population, including the studies IMbrave150, HIMALAYA, CheckMate 459, COSMIC‐312, REFLECT, and LEAP‐002.16, 17, 18, 19, 20, 21